Clinical trial · Observational
Patient-reported Outcomes Following Percutaneous Ablation of Desmoid Tumors
NCT07755176CI-TRIAL-00121262enrolling by invitationClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study will evaluate patient-reported outcomes before and after percutaneous ablation of desmoid tumors. Adult participants undergoing ablation for desmoid tumor will complete surveys pre and post procedure to assess symptom burden, impact on daily life, early post-procedural pain and recovery, concomitant treatments, and radiological response following ablation.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Aggressive Fibromatoses | Desmoid Fibromatosis | ALIAS | 0.90 |
| Desmoid Tumor | Desmoid Fibromatosis | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Desmoid tumor ablation | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Desmoid Tumor Ablation Cohort
- description
- Adult participants undergoing percutaneous ablation for desmoid tumor who complete patient-reported outcome surveys before and after treatment.
- interventionNames
- Procedure: Desmoid tumor ablation
Primary outcomes (3)
- measure
- Change in desmoid tumor symptom severity following ablation
- timeFrame
- Baseline; 7 days; 1, 3, 6, 12, and 24 months post-ablation
- description
- Desmoid tumor symptom severity following ablation will be measured using the GODDESS© Desmoid Tumor Symptom Scale, a disease-specific patient-reported outcome measure assessing desmoid tumor-related symptoms. Scores will be calculated according to the validated GODDESS© scoring algorithm. Higher scores indicate greater symptom burden.
- measure
- Change in desmoid tumor impact following ablation
- timeFrame
- Baseline; 7 days; 1, 3, 6, 12, and 24 months post-ablation
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Adult patients undergoing ablation for desmoid tumor. Exclusion Criteria: * Declines to participate in research.
References
Publications (0)
Data not yet available
No reference posted for this study.